448 results on '"Döhner, Konstanze"'
Search Results
2. Wer ist ... Konstanze Döhner?
3. AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology
4. Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
5. Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
6. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
7. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel
8. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
9. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
10. P453: NOVEL INSIGHTS INTO MINIMAL RESIDUAL DISEASE OF ACUTE MYELOID LEUKEMIA USING PRIMARY SAMPLES AND A CLINICALLY RELEVANT PDX MODEL.
11. P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL
12. S136: ANALYSIS OF FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL IN A LARGE ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENT COHORT: A HARMONY ALLIANCE STUDY
13. P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
14. S120: MNX1-ACTIVATING ENHANCER HIJACKING EVENTS IN ACUTE MYELOID LEUKEMIA WITH DELETIONS ON CHROMOSOME 7Q
15. P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
16. S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
17. P416: DNA METHYLATION-BASED CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA POINTS TOWARDS KDM3B AS A 5Q HAPLOINSUFFICIENCY CANDIDATE
18. P422: TARGETING THE WT1MUT-MIR-193A TRANSCRIPTIONAL AXIS WITH INT-1B3, A NOVEL LIPID NANOPARTICLE-FORMULATED MIR-193A-3P MIMIC IN ACUTE MYELOID LEUKEMIA
19. Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
20. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
21. Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax
22. Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
23. In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts
24. Supplementary Tables 4 - 5 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
25. Figures S1 - S20 from Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML
26. Supplementary Table 1 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
27. Supplementary Table 2 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
28. Figures S1 - S20 from Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML
29. Supplementary Table 3 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
30. Supplementary Table 6 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
31. Supplementary Table 7 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
32. Supplementary Table 6 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
33. Tables S1 - 5 from Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML
34. Supplementary Table 1 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
35. Supplementary Tables 4 - 5 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
36. Supplementary Table 3 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
37. Tables S1 - 5 from Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML
38. Supplementary Table 8 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
39. Supplementary Table 2 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
40. Supplementary Table 7 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
41. Supplementary Figures 1 - 2 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
42. Supplementary Figures 1 - 2 from PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
43. Supplementary Figures 1-4 from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
44. Supplementary Figures 1-4 from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
45. Supplementary Tables 1-2, Figures Legends 1-4 from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
46. Data from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
47. Supplementary Tables 1-2, Figures Legends 1-4 from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
48. Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities
49. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
50. Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.